Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD

European Journal of Cancer 2026

View at publisher
Authors: Zofia Piotrowska, Sarah B. Goldberg, Jonathan W. Goldman, Adrianus J. de Langen, Xiuning Le, Isamu Okamoto, Jonathan W. Riess, Helena A. Yu, Kazumi Nishino, Silvia Novello, Santiago Ponce, Helen Ambrose
+4 more Paul. E. Smith, Kwan Ho Tang, Jonathan M. Lehman, Byoung Chul Cho
DOI: 10.1016/j.ejca.2026.116807
Cited by: 1
References: 24

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Melanoma and MAPK Pathways Colorectal Cancer Treatments and Studies

Publication details

Journal / source
European Journal of Cancer
Publisher
Elsevier BV
Volume
242
Pages
116807–116807
Publication date
18 May 2026
Language
EN